Identifying these reactions is a good start, now we must focus on managing and preventing them
Australia’s voluntary reporting system for adverse drug reactions has one of the highest per capita reporting rates in the world. Reports to the Australian Adverse Drug Reactions Advisory Committee have played a significant international role in identifying previously unrecognised adverse drug reactions (ADRs), such as hepatitis with flucloxacillin and amoxycillin–clavulanic acid.
The full article is accessible to AMA members and paid subscribers. Login to read more or purchase a subscription now.
Please note: institutional and Research4Life access to the MJA is now provided through Wiley Online Library.
- School of Pharmacy and Medical Sciences, University of South Australia, Adelaide, SA.
- 1. Boyd IW. The role of the Australian Adverse Drug Reactions Advisory Committee (ADRAC) in monitoring drug safety. Toxicology 2002; 181-182: 99-102.
- 2. Burgess CL, Holman CDJ, Satti AG. Adverse drug reactions in older Australians, 1981–2002. Med J Aust 2005; 182: 267-270.<eMJA full text>
- 3. Safety and Quality Council. Second national report on patient safety, improving medication safety. Canberra: Australian Council for Safety and Quality in Health Care, 2002.
- 4. Quality Use of Medicines and Pharmacy Research Centre. Measurement of the quality use of medicines component of Australia’s National Medicines Policy. Canberra: Department of Health and Ageing. Available at: www.health.gov.au/internet/wcms/publishing.nsf/Content/nmp-pdf-qumnmp-cnt.htm (accessed Jan 2005).
- 5. National Centre for Classification in Health. International statistical classification of diseases and related health problems, 10th revision, Australian modification (ICD-10-AM). Vol 5. 3rd ed. Sydney: NCCH, 2002.
- 6. Day RO, Shenfield G, Smith AJ. The Quality in Australian Health Care Study (QAHCS): drug related adverse events. Presented at the Australasian Society of Clinical and Experimental Pharmacologists and Toxicologists (ASCEPT) Conference, 1995; Adelaide, SA.
- 7. Lau PM, Stewart K, Dooley M. The ten most common adverse drug reactions (ADRs) in oncology patients: do they matter to you? Support Care Cancer 2004; 12: 626-633.
- 8. National Prescribing Service. Evaluation report no. 7. Sydney: NPS, 2004.
- 9. Weatherby LB, Nordstrom BL, Fife D, Walker AM. The impact of wording in “Dear doctor” letters and in black box labels. Clin Pharmacol Ther 2002; 72: 735-742.
- 10. Roughead EE, Barratt JD, Gilbert AL. Medication-related problems commonly occurring in an Australian community setting. Pharmacoepidemiol Drug Saf 2004; 13: 83-87.
- 11. Benton M, Snow K, Parr V. Evaluation of the medicines information for consumers (MIC) program. A marketing research report prepared for the Pharmacy Guild of Australia. Sydney: Taylor Nelson Sofres plc, 2004. Available at: www.guild.org.au/public/researchdocs/MICfinal_rep_9Nov04.pdf (accessed Jan 2005).
- 12. Gilbert AL, Barrat JD, Roughead EE. Medication management services: alleviating adverse drug reactions. Pharmacoepidemiol Drug Saf 2002; 11 Suppl 1: S39.
- 13. Pharmacy Guild of Australia. Cumulative national HMR claims. Available at: www.guild.org.au/public/dmmrfiles/statscumulnat.pdf (accessed Dec 2004).
- 14. Health Insurance Commission. Medicare Benefits Schedule (MBS) item statistics reports. Available at: www.hic.gov.au/statistics/dyn_mbs/forms/mbs_tab4.shtml (accessed Dec 2004).
- 15. Mitchell GK, de Jong IC, Del Mar CB, et al. General practitioner attitudes to case conferences: how can we increase participation and effectiveness? Med J Aust 2002; 177: 95-97. <MJA full text>